Switch from abciximab to eptifibatide during percutaneous coronary intervention

International Journal of Cardiology

Volumn 134, Issue 3, 2009, Pages 393-400

  Wahlin, Magnus ^a   Albertsson, Per ^a   Karlsson, Thomas ^a   Matejka, Göran ^a   Odell, Annika ^a   Tahmasebiepour, Farshad ^a   Wolmeryd, Christina ^a   Grip, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antithrombotic therapy; Glycoprotein IIb IIIa inhibitors; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; BOLUS INJECTION; CONTINUOUS INFUSION; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALSE ANEURYSM; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATOMA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; ST SEGMENT ELEVATION; STROKE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 67349163260     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.03.008     Document Type: Article

References (32)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
3. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349 (1997) 1429-1435
4. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoptotein IIb/IIIa blockade. Lancet 352 (1998) 87-92
5. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98 (1998) 734-741
6. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
7. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
8. Antoniucci D., Migliorini A., Parodi G., et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 109 (2004) 1704-1706
9. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96 (1997) 1445-1453
10. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344 (2001) 1888-1894
11. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT)): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
12. Amoroso G., van Boven A.J., van Veldhuisen D.J., et al. Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol 38 (2001) 633-641
13. Detre K.M., Holmes Jr. D.R., Holubkov R., et al. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 82 (1990) 739-750
14. Barnathan E.S., Schwartz J.S., Taylor L., et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 76 (1987) 125-134
15. Laskey M.A., Deutsch E., Barnathan E., and Laskey W.K. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol 65 (1990) 1425-1429
16. Schömig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996) 1084-1089
17. Bertrand M.E., Rupprecht H.J., Urban P., and Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
18. Collet J.P., Montalescot G., Lison L., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103 (2001) 658-663
19. Moshfegh K., Redondo M., Julmy F., et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 36 (2000) 699-705
20. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody FAB 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
21. Dalby M., Montalescot G., Bal dit Sollier C., et al. Eptifibatide provides additional platelet inhibition in non-ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 43 (2004) 162-168
22. Anderson K.M., Califf R.M., Stone G.W., et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 37 (2001) 2059-2065
23. Kastrati A., Mehilli J., Schühlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
24. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA 295 (2006) 1531-1538
25. Coons J.C., Seybert A.L., Saul M.I., Kirisci L., and Kane-Gill S.L. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Ann Pharmacother 39 (2005) 1621-1626
26. Deliargyris E.N., Upadhya B., Applegate R.J., Kutcher M.A., Gandhi S.K., and Sane D.C. Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. I Invasive Cardiol 16 (2004) 611-616
27. Suleiman M., Gruberg L., Hammerman H., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invasive Cardiol 15 (2003) 319-323
28. Schweiger M.J., Changezi H.U., Naglieri-Prescod D., and Cook J.R. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin Ther 25 (2003) 225-234
29. Ajani A.E., Waksman R., Gruberg L., et al. Acute procedural complications and in-hospital events after percutaneous coronary interventions: eptifibatide versus abciximab. Cardiovasc Radiat Med 4 (2003) 12-17
30. Leung V.W., Sunderji R., Zed P.J., and Gin K. Switching from abciximab to eptifibatide for percutaneous coronary interventions: a local analysis (SWAP study). Can J Cardiol 19 (2003) 809-814
31. The PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 141 (2001) 402-409
32. Lage M.J., Barber B.L., McCollam P.L., Bala M., and Scherer J. Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients. Catheter Cardiovasc Interv 53 (2001) 296-303